Travere Therapeutics (TVTX) Convertible Debt (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Convertible Debt came in at $312.1 million in Q1 2026, little changed YoY from $310.7 million in Q1 2025, and little changed on a QoQ basis from $311.7 million in Q4 2025.
Travere Therapeutics (TVTX) Convertible Debt (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 15 years of Convertible Debt data on file, last reported at $312.1 million in Q1 2026.
- Quarterly Convertible Debt changed 0.46% year-over-year to $312.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.1 million (changed 0.46% YoY) and the FY2025 annual result came in at $311.7 million, changed 0.46% from the prior year.
- Convertible Debt was little changed at $312.1 million in Q1 2026, from $311.7 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $378.1 million in Q2 2024 to a low of $310.0 million in Q3 2024.
- A 5-year average of $349.4 million and a median of $374.7 million in 2022 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2022 — Convertible Debt surged 71.65% — and 2025, when it retreated 17.75%.
- Tracing TVTX's Convertible Debt over 5 years: stood at $375.5 million in 2022, then grew by 0.46% to $377.3 million in 2023, then decreased by 17.75% to $310.3 million in 2024, then gained by 0.46% to $311.7 million in 2025, then climbed by 0.11% to $312.1 million in 2026.
- The last three Convertible Debt figures came in at $312.1 million (Q1 2026), $311.7 million (Q4 2025), and $311.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 602.78 Mn |
| Mar 31, 2026 | 312.08 Mn |
| Dec 31, 2025 | 311.72 Mn |
| Sep 30, 2025 | 311.37 Mn |
| Jun 30, 2025 | 311.02 Mn |
| Mar 31, 2025 | 310.66 Mn |
| Dec 31, 2024 | 310.31 Mn |
| Sep 30, 2024 | 309.96 Mn |
| Jun 30, 2024 | 378.13 Mn |
| Mar 31, 2024 | 377.69 Mn |
| Dec 31, 2023 | 377.26 Mn |
| Sep 30, 2023 | 376.83 Mn |
| Jun 30, 2023 | 376.40 Mn |
| Mar 31, 2023 | 375.97 Mn |
| Dec 31, 2022 | 375.55 Mn |
| Sep 30, 2022 | 375.12 Mn |
| Jun 30, 2022 | 374.69 Mn |
| Mar 31, 2022 | 374.33 Mn |
| Dec 31, 2021 | 226.58 Mn |
| Sep 30, 2021 | 223.70 Mn |